Large-scale testing (Phase 3)Study completedNCT00420316
What this trial is testing
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
Who this might be right for
Infections, Rotavirus
GlaxoSmithKline 1,613